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40-word summary: In our study of 117 organ-transplant recipients with nocardiosis, a history of tumor, 
invasive fungal infection, donor age and no acute rejection were independently associated with one-year 
mortality. Short-course antibiotic treatment (≤120 days), used in 17 patients, appeared promising.  
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ABSTRACT  
Background: Solid organ transplant (SOT) recipients are at risk of nocardiosis, a rare opportunistic bacterial 
infection, but prognosis and outcome of these patients are poorly defined. Our objectives were to identify 
factors associated with one-year mortality after nocardiosis and describe the outcome of patients receiving 
short-course antibiotics (≤120 days).  
Methods: We analyzed data from a multicenter European case-control study that included 117 SOT recipients 
with nocardiosis diagnosed between 2000 and 2014. Factors associated with one-year all-cause mortality were 
identified using multivariable conditional logistic regression. 
Results: One-year mortality was 10-fold higher in patients with nocardiosis (16.2%, 19/117) than in control 
transplant recipients (1.3%, 3/233, p<0.001). A history of tumor (odds ratio [OR] 1.4; 95% confidence interval 
[CI] 1.1-1.8), invasive fungal infection in the six months before nocardiosis (OR 1.3; 95%CI 1.1-1.5) and donor 
age (OR 1.0046; 95%CI 1.0007-1.0083) were independently associated with one-year mortality. Acute rejection 
in the year before nocardiosis was associated with improved survival (OR 0.85; 95%CI 0.73-0.98). Seventeen 
patients received short-course antibiotics (median duration 56 [24-120] days) with a one-year success rate 
(cured and surviving) of 88% and a 5.9% risk of relapse (median follow-up 49 [6-136] month). 
Conclusions: One-year mortality was 10-fold higher in SOT patients with nocardiosis than in those without. 
Four factors, largely reflecting general medical condition rather than severity and/or management of 
nocardiosis, were independently associated with one-year mortality. Patients receiving short-course antibiotic 
treatment had good outcomes, suggesting this may be a strategy for further study.  
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LIST OF ABBREVIATIONS 
16S rRNA: 16S ribosomal ribonucleic acid 
95% CI:  95% confidence interval 
ATG:  antithymocyte globulin 
CCI:  Charlson comorbidity index 
CMV:  cytomegalovirus 
CNS:  central nervous system 
CRP:   C-reactive protein 
NS:  not significant 
OFN:  Observatoire Français des Nocardioses 
OR:  odds ratio 
SOT:  solid organ transplantation 
spp.:  species 
SXT:   trimethoprim–sulfamethoxazole (cotrimoxazole) 
 
 
 
 
  
INTRODUCTION 
Nocardia spp. is a filamentous environmental Gram-positive bacterium that causes infection in 
immunocompromised patients, such as solid organ transplantation (SOT) recipients [1]. Because inhalation is 
the main portal of entry for Nocardia, lung involvement is frequent and bacteria may subsequently spread to 
other organs, such as the brain [1].  
Although several reports have indicated that nocardiosis is associated with increased mortality in SOT 
recipients, a precise assessment of its impact on outcome is still lacking [2]. Indeed, reported post-SOT 
nocardiosis mortality rates vary from 0 to 70%, depending on the characteristics of the studied populations and 
durations of follow-up [3-8]. Furthermore, prognostic factors have not been precisely identified, because only 
limited-size retrospective studies have been published. Of note, a univariate analysis performed in a study of 
31 patients with nocardiosis (including nine transplant recipients) suggested that dissemination and presence 
of brain abscesses were associated with increased mortality [9].  
Theoretically, factors that could influence the outcome of nocardiosis include its presentation (e.g., presence of 
cerebral abscesses [9]), possible co-infections with other opportunistic pathogens (e.g., Aspergillus and 
cytomegalovirus [CMV] [6]), therapeutic modalities (e.g., appropriateness of antibiotics according to species 
identification and antimicrobial susceptibility testing [2]), occurrence of adverse effects associated with 
antibiotics (e.g., toxicity of trimethoprim–sulfamethoxazole [SXT] [6, 10, 11]) and presence of co-morbidities 
[12]. Improved understanding of the impact of nocardiosis on outcomes after SOT and of factors associated 
with outcomes may help delineate a group of patients requiring a specific initial diagnostic work-up, treatment 
and/or follow-up.   
Another challenge in the field of post-SOT nocardiosis is the optimal duration of antibiotic treatment with 
regard to the risk of relapse on the one hand and to the adverse effects and costs of these agents on the other. 
Current recommendations suggest at least six months of antimicrobial therapy for pulmonary or soft tissue 
infections and a minimum of 9-12 months for brain abscess [13]. These guidelines are based on a retrospective 
study of 25 pulmonary cases published in 1982 that described a high rate of relapse (60%, 3/5 patients) among 
patients who received SXT alone for less than four months [14]. Strikingly, a more recent study that included 12 
heart transplant recipients suggested that a shorter (≤120 days) treatment course was feasible in pulmonary 
nocardiosis, without relapse [15].  
We recently reported the results of a multicenter case-control study conducted to identify risk factors for 
nocardiosis [16]. In the present study, our primary objective was to identify factors associated with all-cause 
mortality one year after diagnosis of nocardiosis in the SOT population. Our secondary objective was to assess 
the risk of relapse associated with short-course (≤120 days) antibiotic treatment for Nocardia infection. 
 
  
MATERIAL AND METHODS 
Study design and participants 
In our previously published retrospective case-control study, 351 SOT recipients (117 patients with post-
transplant nocardiosis and 234 matched control transplant recipients, details of whom can be found elsewhere 
[16]) were included from 36 hospitals in Western Europe (participating centers are listed in the Appendix and in 
the author list) [16]. The present study includes the same 351 patients. Patients with nocardiosis were included 
if they met all the following criteria: (1) SOT recipient; (2) isolation of Nocardia spp. in a clinical sample after 
transplant; (3) signs and/or symptoms suggestive of nocardiosis; (4) diagnosis made between January 2000 and 
December 2014. To avoid selection bias, cases were identified in each institution using systematic and 
comprehensive screening of local microbiological, pathology and transplantation databases.  
 
Variables 
Data were collected from the patients’ medical records by local investigators using dedicated case-report 
forms. The date of diagnosis was defined as the day on which the first clinical sample (e.g., sputum) that 
allowed identification of Nocardia spp. was collected. Variables potentially associated with patient outcome 
were divided into three groups: 
(1) Collected patient characteristics included: age, sex, comorbidities at time of nocardiosis (Charlson 
Comorbidity Index (CCI), Supplementary Table 1) [17], transplant details (history of previous transplant, donor 
age,  type of donation (deceased vs. living), organ transplanted), immunosuppressive regimen used, history of 
acute allograft rejection and history of opportunistic infections (CMV infection and/or disease as defined 
elsewhere [18], CMV serostatus at time of transplantation, bloodstream infection and history of treated proven 
or probable invasive fungal infection in the six months before nocardiosis). High-dose corticosteroids were 
defined as >20 mg/day of prednisone for at least one month or >2 pulses of 500 mg of intravenous 
methylprednisolone. High calcineurin inhibitor trough levels were defined as >10 ng/mL for tacrolimus and 
>300 ng/mL for cyclosporine. 
(2) Factors related to the characteristics of nocardiosis included: time from transplant to nocardiosis, time 
between occurrence of symptoms and diagnosis, sites of infection, eventual dissemination (defined as the 
involvement of at least two non-contiguous organs and/or positive blood cultures), biological blood values at 
the time of Nocardia infection (kidney function, C-reactive protein, leukocytes, neutrophils, lymphocytes), 
additional pathogens (identification of at least one other microbial pathogen at the time of Nocardia 
diagnosis), Nocardia species, susceptibility to SXT.  
(3) Factors associated with the treatment of nocardiosis included the antimicrobial agents used, 
appropriateness of the antimicrobial agents prescribed in the first two weeks of therapy in the initial regimen 
(appropriateness being defined as the administration of antibiotics with in vitro activity against the infecting 
strain [19]), use of bactericidal antibiotics (amikacin, carbapenems, third-generation cephalosporin restricted 
to ceftriaxone and cefotaxime [20]) in the first two weeks of treatment, occurrence of antibiotic-related 
adverse effects and need for surgery due to nocardiosis. Total duration of antibiotic treatment was recorded 
and a short-course was defined as ≤120 days [15].  
Relapse was defined as the association of clinical and radiological signs of nocardiosis with isolation of the 
same Nocardia species found at initial diagnosis, after the cessation of antimicrobial treatment for nocardiosis. 
Determination of nocardiosis as the cause of death was based on physician analysis of the medical chart. 
 
Microbiology 
To identify the species of each Nocardia strain, amplification and sequencing of a fragment of the gene coding 
for the 16S ribosomal RNA (16S rRNA) or hsp65 genes were mandatory, as described previously [16]. Ideally, 
antibiotic susceptibility testing was performed by determination of the minimal inhibitory concentration (MIC) 
in broth microdilution [21] but MICs evaluated by E-test® strips or antibiotic disk diffusion on agar plates were 
considered acceptable when performed by a trained microbiologist [22-25]. When antibiotic susceptibility 
testing was missing, stored strains were a posteriori sent to the French expert laboratory for nocardiosis 
(Observatoire Français des Nocardioses, Lyon, France) to perform the missing tests. 
 
Statistical methods 
Final analysis was conducted after all data had been recorded and verified. Continuous data are presented as 
median (range) or mean (± standard deviation), as appropriate. Categorical data are presented as numbers and 
percentage of total. The primary outcome was survival 12 months after diagnosis of Nocardia infection. 
Survival was assessed using Kaplan-Meier curves and compared between groups using log-rank tests. 
Univariate analyses were performed using Fisher’s exact test or chi-square test, as appropriate, to compare 
categorical variables, and Student t-tests were performed to compare continuous variables. A bilateral p-value 
<0.05 was considered as statistically significant. Variables with a p-value <0.2 on univariate analysis were 
included in the final multivariable conditional logistic regression analysis. All statistical analyses were 
performed using R Statistical software (version 3.2.0; R Foundation for Statistical Computing, Vienna, Austria). 
 
Ethical aspects 
As previously described, this work was approved by local ethics committees and fulfilled the regulatory 
standards of each participating country [16].  
 
  
RESULTS 
Participants and overall mortality 
One hundred and seventeen SOT recipients with nocardiosis were included from 36 European institutions; full 
case descriptions can be found elsewhere [16]. The median duration of follow-up from the date of nocardiosis 
diagnosis was 45.3 [0.1-151.9] months. One-year all-cause mortality was significantly higher in patients with 
nocardiosis (16.2%, 19/117) than in control transplant patients (1.3%, 3/233) (p<0.001) (Figure 1A). In the 
nocardiosis non-survivors, death occurred after a median of 134 [4-359] days post-infection. Nocardiosis was 
listed as the cause of death in 52.6% of the non-survivors (10/19); when comparing deaths related or not to 
nocardiosis, there was no statistically significant difference in the length of time between nocardiosis and 
death (100 [19-302] days vs. 149 [4-359] days, p=0.57). 
 
Prognostic factors 
In univariate analysis (Table 1), one-year mortality was significantly higher in patients with an additional 
pathogen at the time of diagnosis of nocardiosis, invasive fungal infection in the six months before nocardiosis, 
older donor age and longer time from transplantation to nocardiosis (all p<0.05). No therapeutic variables were 
associated with survival at one year. In multivariable analysis (Table 2), history of tumor (defined as a non-
metastatic tumor [if active or initially treated in the 5 years before diagnosis of nocardiosis] or metastatic solid 
tumor), invasive fungal infection in the six months before nocardiosis and older donor age were independently 
associated with increased one-year mortality. Conversely, acute rejection in the year before nocardiosis was 
associated with a better survival. Survival analyses are shown in Figures 1B to D.  
 
Description of initial management  
During the first two weeks of treatment, appropriate antibiotics were prescribed in 94.6% of the patients 
(105/111) based on results of antibiotic susceptibility testing (Supplementary Tables 2 and 3). Bactericidal 
antibiotics were used as initial therapy in 66/109 of the patients (60.6%) and two simultaneous appropriate 
antibiotics in 48/111 (43.2%). At least one antibiotic-attributed adverse effect was reported in 46.6% of the 
patients (54/116), affecting the bone marrow (n=24), kidneys (n=22), digestive system (n=11) and/or skin (n=5). 
Twenty-three patients required surgery (23/117, 19.7%). 
 Risk of relapse and short-course antibiotic treatment 
Twenty-seven patients (23.0%) received short-course antibiotic treatment. However, the impact of antibiotic 
duration on the risk of relapse could only be assessed in 17 patients, as death occurred within 120 days in 10 of 
these patients (37.0%). These 10 patients died while still receiving active antimicrobial therapy against 
Nocardia and half of these deaths (5/10) were directly attributed to nocardiosis. A detailed description of the 
17 analyzable patients is provided in Table 3; the median duration of antibiotic treatment was 56 [24-120] 
days. Compared with the entire cohort, the 17 patients in whom antibiotics were deliberately given for ≤120 
days were less likely to have disseminated disease (2/17 [11.8%] vs. 50/117 [42.7%], p<0.01) and tended to less 
frequently have CNS infection (1/17 [5.9%] vs. 30/117 [25.6%], p=0.12). After a median follow-up of 49 [6-136] 
months, 15 of the 17 patients were cured (88.2%, including 2/2 with disseminated infection, 1/1 with CNS 
infection and 11/12 with lung infection), one died within the first year (5.9%) and one relapsed (5.9%). The 
patient who died had Candida bloodstream infection at the time of diagnosis. Among the 15 patients who did 
not relapse despite administration of short-course antibiotics, all received appropriate initial antibiotics (15/15, 
100%) but the percentages of patients who received bactericidal antibiotics (7/15, 46.7%) or an association of 
two appropriate antibiotics (5/15, 33.3%) in the first two weeks of treatment were not significantly different to 
those observed in the entire cohort (p=0.46 and p=0.65 respectively). After cessation of therapy, secondary 
prophylaxis with SXT was given to 62.5% (10/16) of the patients who had received short-course antibiotics. 
Seven patients (7/117, 6.0%) had a relapse during follow-up. These patients had a median duration of 
treatment of 165 [51-501] days with one patient receiving short-course treatment (51 days). This patient, who 
had isolated lung infection, had relapsing nocardiosis despite the use of appropriate and bactericidal antibiotics 
in the first two weeks of treatment. Among the 7 patients who relapsed, a single one died within one year, due 
to an episode of acute allograft rejection. 
Among 98 survivors at one year, 92 (93.9%) had no relapse after a median follow-up of 4.3 [1-12.6] years. 
Among these survivors, the median duration of treatment was 195 [24-1981] days. Duration of antibiotic 
treatment was significantly longer in patients with disseminated or CNS nocardiosis (Supplementary Figure 1).  
In the 8/117 patients who had an infection limited to the skin and soft-tissues (6.8%), the median duration of 
antibiotic treatment was 103 [35-351] days and 6 of these patients (75.0%) required surgery. Cure was 
achieved in 7 patients (87.5%, including 4 patients with short-course antibiotics) and one patient (12.5%) 
relapsed 137 days after the end of therapy (which included >4 months of antibiotics and no surgery). 
  
DISCUSSION 
In our European cohort, one-year all-cause mortality was more than ten-times higher in the 117 SOT recipients 
with nocardiosis than in control transplant recipients. Four factors were independently associated with risk of 
death one year after nocardiosis: a history of tumor, invasive fungal infection in the 6 months before 
nocardiosis, donor age and absence of acute organ rejection in the year before nocardiosis.  
The mortality rate observed in our study (16.2%, 19/117) is comparable to that in a previous study reporting on 
35 patients with post-SOT nocardiosis (6-month mortality=14.3%, 5/35) [6] but appears to be lower than in 
other reports (~30%) [4, 5]. This apparent discrepancy may be explained by the different outcome periods used 
in the various studies and the large proportion of lung recipients in the two latter studies. Higher mortality 
rates have been reported in patients with fungal opportunistic infections after SOT, including pneumocystosis 
(90-day mortality 23.1%, 6/26) [26], aspergillosis (12-week mortality, 39.3%, 44/112) [27] and mucormycosis 
(90-day mortality 58.2%, 57/105) [27]. We were, therefore, not surprised to observe that occurrence of an 
invasive fungal infection in the 6 months prior to nocardiosis (reported in 17.0% of our cohort and in 37.5% of 
the patients who died) was independently associated with an increased risk of death, as has been suggested 
previously [8].  
Other patient characteristics were also independently associated with death after nocardiosis. First, we 
observed that a history of tumor was an independent prognostic factor after nocardiosis. Second, donor age 
was independently associated with one-year mortality, an observation that is in agreement with data from the 
French transplantation agency (Agence de la Biomédecine) reporting that donor age was associated with 
reduced graft and recipient survival after heart, lung, liver and kidney transplantation [28].  
Of interest, we observed significantly lower mortality among patients who experienced an acute rejection 
episode in the year before nocardiosis. Although this observation may appear surprising, these patients tended 
to have received higher doses of corticosteroids in the six months before diagnosis and to more frequently 
have a high calcineurin inhibitor level, suggesting that although a higher degree of immunosuppression may 
increase the risk of post-SOT nocardiosis, it is associated with a better outcome [16]. This association may be 
explained by the fact that patients with a high degree of immunosuppression are more closely monitored and 
promptly investigated in case of fever or respiratory symptoms leading to earlier diagnosis, but one can also 
hypothesize that a greater inflammatory response may be associated with a worse prognosis in Nocardia 
infection.  
Strikingly, no therapeutic variable was associated with patient survival. Because of the non-interventional 
design of our study, we cannot rule out a beneficial effect of the early use of appropriate antibiotics, or the 
impact of using antibiotic combinations or bactericidal versus bacteriostatic antibiotics. Expert 
recommendations regarding the initial choice of antibiotics [13] should therefore be followed, initially using 
antibiotics active against a broad spectrum of Nocardia species, such as SXT, amikacin, third-generation 
cephalosporins (restricted to ceftriaxone and cefotaxime), carbapenem (restricted to imipenem and 
meropenem) or linezolid. Antibiotic combinations that include bactericidal antibiotics should be considered for 
severe cases, including CNS nocardiosis. Treatment should be adapted as soon as possible to molecular biology-
based species identification and results of antimicrobial susceptibility testing.  
A somewhat controversial finding when considering current recommendations is our data regarding the 
duration of treatment for nocardiosis. Guidelines propose at least a six-month antibiotic course for nocardiosis, 
but few data are available to support this statement. In 1982, Wallace and co-workers reported 25 cases of 
pulmonary nocardiosis (in patients without SOT) and described a higher rate of relapse among patients 
receiving less than four months of treatment [14]. Almost thirty years later, in a retrospective description of 12 
cases of nocardiosis after heart transplantation who received short-course (≤120 days) antibiotic treatment, 
Tripodi et al [15] reported that none of their patients who were treated with 3-4 weeks of intravenous 
bactericidal antibiotics followed by 1-3 months of oral antibiotic relapsed. Reducing antibiotic treatment 
duration could have potential benefits, such as cost-savings and reduction in the risk of adverse events, 
especially among transplant recipients. Indeed, 46.5% of our patients experienced at least one drug-related 
adverse effect. Among 17 analyzable patients (including only two with disseminated infection and one with 
CNS infection) receiving short-course antibiotic treatment frequently followed by secondary prophylaxis with 
SXT, we observed an 88.2% cure rate without relapse, one nocardiosis-independent death and one relapse. Our 
results should be interpreted with caution because of the risk of selection bias associated with the non-
randomized design but, together with the findings of Tripodi et al [15], support the need for a randomized 
controlled trial on the duration of antibiotic treatment for nocardiosis. Such a study should take into account 
important factors that were not available in our study (e.g., dosing of antibiotics, potential reduction or 
tapering of immunosuppressive drugs, patient compliance). However, the relatively low number of events 
(<20% deaths at one year and rare relapses) observed in our study and the rarity of nocardiosis after SOT 
would make such a trial difficult to perform. 
Once therapy is stopped, the role of secondary prophylaxis using low-dose SXT has not yet been determined. 
Secondary prophylaxis with SXT was prescribed to 62.5% (10/16) of our patients receiving short-course 
antibiotic treatment, which may explain the low incidence of relapse. However, we and others have shown 
previously that the low doses of SXT used to prevent pneumocystosis after SOT are not effective as primary 
prophylaxis against nocardiosis [16]. Because such prophylaxis is usually well tolerated and also prevents other 
opportunistic infections, we would recommend its use at higher dosage (800 mg sulfamethoxazole per day) as 
secondary prophylaxis.  
Our study has several limitations, including its retrospective design, lack of data regarding reduction or tapering 
of immunosuppressive drugs or compliance to therapy, and the fact that antibiotic dose adjustment to body 
weight or kidney function was not taken into account. The limited size of our study and its design may explain 
the absence of a significant association between the severity of nocardiosis (e.g., presence of brain abscess) 
and mortality [9]. Antibiotic susceptibility testing was not standardized with only 40% of the bacterial strains 
sent to the French expert laboratory and most tests were performed by antibiotic disk diffusion on agar plates. 
However, although disk diffusion is not considered a gold-standard by the CLSI, it has been shown to have a 
high percentage agreement with reference methods [21, 22]. 
In conclusion, we provide the first assessment of factors associated with one-year mortality after post-SOT 
nocardiosis. Our findings support the suggestion that short-course antibiotic treatment may be a strategy for 
further study. 
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Figure 1. One-year survival curves after diagnosis of post-solid organ transplantation nocardiosis. Survival 
was assessed using Kaplan-Meier curves and compared among groups using log-rank tests. A. Survival curves of 
patients with nocardiosis (n=117) and matched control transplant recipients (n=234). B to D. Survival curves 
among patients with nocardiosis according to the presence of invasive fungal infection (including Pneumocystis 
pneumonia) in the 6 months before nocardiosis (B), history of tumor defined as a non-metastatic tumor (if 
active or initially treated in the 5 years before diagnosis of nocardiosis) or metastatic solid tumor (C) and 
episode of acute rejection in the year before nocardiosis (D). 
 
  
Table 1. Factors associated with one-year all-cause mortality in univariate analysis among the 117 patients 
with post-solid organ transplantation nocardiosis. 
Characteristics 
Dead 
at 1 year 
n=19 
Alive 
at 1 year 
n=98 
 
p-value 
Clinical characteristics    
 Age at diagnosis (years) (mean ± SD) 61.4 (12.3) 54.5 (13.5) 0.07 
 Male (n, %) 14 (73.7) 60 (61.2) 0.44 
 Charlson comorbidity index† at diagnosis n=112 (mean, SD) 4.13 (1.7) 3.71 (1.8) 0.34 
 History of tumor ‡ n=112 3 (18.8) 5 (5.2) 0.08 
Transplantation characteristics     
 History of previous transplant  1 (5.2) 17 (17.3) 0.30 
 Donor age (mean ± SD) n=110  54.5 (15.8) 46.0 (16.8) 0.044  
 Deceased donor (vs living) 18 (94.7) 89 (90.8) 1 
 Non-thoracic (pancreas, liver, kidney) organ 12 (63.2) 66 (67.3) 0.79 
Immunosuppressive regimen and rejection data    
 Cyclosporine A at diagnosis  4 (21.1) 17 (17.3) 0.75 
 Tacrolimus at diagnosis  15 (78.9) 78 (80.0) 1 
 High CNI level in the month before Nocardia infection 5 (26.3) 46 (46.9) 0.16 
 Use of antiproliferative agents (AZA or MMF) at diagnosis  14 (73.7) 81 (82.7) 0.35 
  Corticosteroids at diagnosis (mg*) (mean ± SD) n=115 7.0 (4.0) 9.1 (7.2) 0.12 
 Acute rejection episode in the year before diagnosis n=116 2 (10.5) 30 (30.6) 0.09 
  Acute rejection episode in the six months before diagnosis 
n=116 
1 (5.3) 24 (24.5) 0.07 
  High-dose steroids in the six months before diagnosis n=116 1 (5.3) 19 (19.4) 0.19 
  Plasma exchange in the six months before diagnosis n=116 0 (0) 5 (5.1) 0.59 
  Depleting antibodies** (ATG or Rituximab) in the six months 
before diagnosis n=116 
0 (0) 6 (6.1) 0.59 
  SXT prophylaxis at diagnosis  2 (10.5) 19 (19.4) 0.52 
Associated infectious diseases    
 CMV infection in the six months before diagnosis 3 (15.8) 14 (14.3) 1 
 CMV disease in the six months before diagnosis  2 (10.5) 3 (3.1) 0.19 
 CMV serostatus     0.67 
  Low risk: D-R- 5 (26.3) 17 (17.3)  
  Intermediate risk: D-R+ or D+R+ 10 (52.6) 50 (51.0)  
  High risk: D+R- 4 (21.1) 27 (27.6)  
 Bloodstream infection in the six months before diagnosis  1 (5.3) 5 (5.1) 1 
 Additional pathogen
$ at diagnosis  12 (63.2) 28 (28.6) < 0.01 
 Fungal infection
#
 in the six months before diagnosis n=112 
 
6 (37.5) 13 (13.5) 0.029 
Biological characteristics    
 Glomerular filtration rate ¶ (ml/min/1.73m
2
) at diagnosis 
(mean, SD) n=115 
41.4 (24.3) 50.1 (27.6) 0.19 
 WBC count at diagnosis (x1000/mm
3
) (mean, SD) n=115  11.3 (5.8) 11.5 (6.7) 0.88 
 Neutrophil count at diagnosis (x1000/mm
3
) (mean, SD) n=105 9.5 (5.6) 9.8 (6.7) 0.98 
 Lymphocyte count at diagnosis (x1000/mm
3
) (mean, SD) n=105 0.6 (0.4) 0.8 (0.6) 0.35 
 C-reactive protein at diagnosis (mg/L) (mean, SD) n=109 91.8 (67.5) 128.4 (90.9) 0.13 
Nocardiosis characteristics and treatment    
 Time from transplantation to diagnosis (days) (mean, SD) 1611.7 
(1692.7) 
976.2 
(1277.7) 
0.046 
 Time from symptoms to diagnosis (days) (mean, SD) n=114 19.4 (18.4) 25.9 (24.1) 0.21 
 Disseminated infection  9 (47.4) 41 (41.8) 0.85 
 Lung or pleural involvement 16 (84.2) 85 (86.7) 0.72 
 Central nervous system involvement 8 (42.1) 22 (22.4) 0.13 
 Skin and soft-tissue involvement 5 (26.3) 32 (32.7) 0.78 
 Bloodstream infection  2 (10.5) 7 (7.1) 0.64 
 Nocardia species    0.33 
  N. farcinica 8 (42.1) 33 (33.7)  
  N. non-farcinica  11 (57.9) 65 (66.3)  
 Strain susceptible to SXT n=113 14 (73.7) 85 (86.7) 0.44 
 Appropriate antibiotics
$
 during the first two weeks of 
treatment n=111 
15 (88.2) 90 (95.7) 0.23 
 Administration of carbapenems, 3GC, amikacin or SXT during 
the first two weeks of treatment n=113 
15 (83.3) 89 (93.7) 0.15 
 Bactericidal antibiotic (carbapenems, 3GC, amikacin) during 
the first two weeks of treatment n=109 
10 (62.5) 56 (60.2) 1 
 Association of two appropriate antibiotics during the first two 
weeks of treatment n=111 
7 (41.2) 41 (43.6) 1 
 Antibiotic-related adverse effects n=116 9 (47.4) 45 (46.4) 1 
 Need for surgery  4 (21.1) 19 (19.4) 1 
NOTE. 3GC: Third-generation cephalosporin (restricted to ceftriaxone and cefotaxime); ATG: antithymocyte globulin; AZA: 
azathioprine; CMV: cytomegalovirus; CNI: calcineurin inhibitor; diagnosis: date of the diagnosis of nocardiosis; MMF: 
mycophenolate mofetil; n: number of data analyzed (when <117); PCP: Pneumocystis pneumonia; SD: standard deviation; 
SXT: trimethoprim–sulfamethoxazole; WBC: white blood cell. Data are n (%) unless otherwise indicated.  
†Apart from “history of tumor”, none of the other individual variables of the Charlson comorbidity index were associated 
with one-year mortality, with p-values > 0.2. ‡ defined as a non-metastatic tumor (if active or initially treated in the 5 
years before diagnosis of nocardiosis) (n=7) or metastatic solid tumor (n=1). *All the corticosteroid doses are expressed in 
milligrams (mg) of methylprednisolone equivalent per day. **In the 6 months before diagnosis of Nocardia infection, 
none of our patients received other types of lymphocyte-depleting or modulating antibodies. ¶As estimated by MDRD 
formula. 
$
Fifty-one additional microbial pathogens were identified at time of nocardiosis among forty patients: 19 fungi, 
11 CMV, 8 Gram-negative bacteria, 4 Gram-positive bacteria, 3 C. difficile, 2 Legionella spp., 1 HHV8, 2 other viruses and 1 
Toxoplasma gondii. 
#
19 patients experienced at least one invasive fungal infection (10 aspergillosis, 3 mucormycosis, 3 
invasive candidiasis, 2 Alternaria spp., 1 Fusarium spp., 1 Scedosporium spp., 1 Pneumocystis). 
$
Appropriate antibiotic is 
defined as a drug with demonstrated in vitro activity against the isolated Nocardia strain. 
 
Table 2. Factors associated with one-year all-cause mortality after multivariable conditional logistic 
regression analysis among 117 patients with nocardiosis after solid organ transplantation. 
 
Characteristics OR [95%IC] p-value 
History of tumor * 1.4 [1.1- 1.8] 0.02 
Fungal infection† in the 6 months before diagnosis 1.3 [1.1-1.5] < 0.01  
Donor age (per year) 1.0046  
[1.0007-1.0083] 
0.02 
Acute rejection episode in the year before diagnosis 0.85 [0.73-0.98] 0.03 
NOTE. *defined as a non-metastatic tumor (if active or initially treated in the 5 years before diagnosis of 
nocardiosis) (n=7) or metastatic solid tumor (n=1). † 19 patients experienced at least one invasive fungal 
infection (10 aspergillosis, 3 mucormycosis, 3 invasive candidiasis, 2 Alternaria spp., 1 Fusarium spp., 1 
Scedosporium spp., 1 Pneumocystis).  
 
Table 3. Description of patients with post-solid organ transplantation nocardiosis receiving short-course antibiotic treatment (≤ 120 days) 
 
Patient 
Age at 
time of 
diagnosis  
Lung involvement † Disseminated 
infection 
CNS 
infection 
Skin 
and 
soft-
tissue 
Type of positive 
sample 
Nocardia 
species 
Antibiotic 
treatment 
duration 
(days) 
Outcome at one year 
Secondary 
prophylaxis 
with SXT, 
dose‡, 
duration* 
Length of 
follow-
up 
(months) 
1 52 Multilobar, bilateral  No No No 
Sputum, bronchial 
aspirate, BAL and 
pleural fluid 
ND 42 Alive, no relapse 
Yes, 
2800, till 
death 
41 
2 67 None No No Yes Abscess fluid N. farcinica 90 Alive, no relapse Yes, 
5600, 6m 
49 
3 50 Unilobar, unilateral  Yes No No Bronchial aspirate, 
BAL and blood N. nova complex 47 Alive, no relapse 
Yes, 
2400, 12m 
48 
4 63 Multilobar, bilateral  No No No Sputum N. farcinica 24 Alive, no relapse Yes, 
1600, ND 
132 
5 36 Multilobar, bilateral  No No No Sputum N. abscessus 51 Relapse, alive at one year Yes, 
1600, ND 
26 
6 56 Multilobar, bilateral  No No No Bronchial aspirate 
and BAL N. nova complex 39 Alive, no relapse 
Yes, 
1200, ND 62 
7 65 Multilobar, unilateral  No No No Bronchial aspirate 
and BAL N. farcinica 76 Alive, no relapse 
Yes,  
2400, 4m 22 
8 69 Multilobar, bilateral  No No No Bronchial aspirate 
and BAL N. farcinica 70 Alive, no relapse No 63 
9 80 None No No Yes Skin biopsy N. flavorosea 56 Alive no relapse No 27 
10 71 None No No Yes Abscess fluid N. farcinica 102 Dead, no relapse* Yes, 
5600, 5m 6 
11 30 Unilobar, unilateral  No No No BAL N. farcinica 45 Alive, no relapse No 23 
12 60 Multilobar, bilateral  No No No BAL N. farcinica 33 Alive at one year, no 
relapse 
Yes, 2400,  
till death 
136 
13 32 None No No Yes Skin biopsy N. abscessus 90 Alive at one year, no 
relapse No 72 
14 60 Unilobar, unilateral  Yes Yes Yes Abscess fluid N. cerradoensis 47 Alive at one year, no 
relapse 
Yes, 2400,  
till death 
15 
15 40 Multilobar, bilateral  No No No Pleural fluid ND 90 Alive at one year, no 
relapse No 133 
16 67 None No No Yes Skin biopsy N. anaemiae 105 Alive at one year, no 
relapse No 86 
17 56 Unilobar, unilateral  No No No Sputum and BAL ND 120 Alive at one year, no 
relapse ND 90 
NOTE. † Lung involvement was assessed with lung CT-scan (CT) for all patients except patients 1 and 9. ‡ dose was expressed as sulfamethoxazole weekly dose in milligrams. * 
Death unrelated to nocardiosis. BAL: bronchoalveolar lavage, CNS: central nervous system, m: months, ND: not determined, SXT: trimethoprim–sulfamethoxazole. 
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